Cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults
Depressive episodes are the most frequent episodes in bipolar disorder. Few treatments, however, have been approved by the FDA for the treatment of bipolar depression. Cariprazine, a broad-spectrum dopamine antagonist/partial agonist with dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist properties, was recently approved. Partial agonism/antagonism at D3 receptors inhibits the activity of somatodendritic D3 […]